Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Finerenone for the Early Regression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

NCT07667517 is registered in ClinicalTrials.gov with First Affiliated Hospital of Zhejiang University as lead sponsor.

NCT NCT07667517
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07667517 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Finerenone for the Early Regression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Lead sponsor
First Affiliated Hospital of Zhejiang University
Phase
Phase 4
Overall status
Not yet recruiting
Start date
July 1, 2026
Completion date
December 31, 2027
Enrollment
148 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

albuminuria, chronic kidney diseases, type 2 diabetes mellitus (t2dm)